Silo Pharma Collaborates on Drug-Device Study for PTSD Treatment Delivery
Silo Pharma partners with Resyca BV for drug-device study on PTSD treatment delivery. CEO highlights potential of microchip-enabled nasal spray system. Impacting innovative therapeutic delivery methods for stress-induced psychiatric disorders.
This news matters as it showcases Silo Pharma's innovative approach to addressing underserved conditions like PTSD and chronic pain. The collaboration with Resyca BV could potentially lead to a breakthrough in therapeutic delivery methods, impacting patients suffering from stress-induced psychiatric disorders.